OBJECTIVE： To analyze the characteristics and laws of ADR induced by monoclonal antitumor drugs， and to provide reference for clinical medication safety. METHODS： 148 cases of ADR induced by monoclonal antitumor drugs were selected from our hospital during Jan. 2012-Feb. 2016， and analyzed statistically in respects of patients’ gender and age， primary disease， drug kind， the occurrence of ADR， clinical manifestations， treatment and outcome， etc. RESULTS： Among 148 ADR cases， there were 80 male and 68 female with ratio of 1.176 5 ∶ 1. High-risk aged 50 to 59 years old （32.43％）； of primary disease， the proportion of non-Hodgkin lymphoma was the highest （37.84％）； 5 kinds of drugs were involved， among which ADR induced by Rituximab injection took up the highest proportion （47.97％）； most of ADR occurred within 1 d after medication （54.73％）； ADR mainly involved digestive system （41.89％）； main clinical manifestations were chronic hepatic fibrosis， loss of appetite， constipation， nausea and vomiting； there were 9 severe ADR cases （6.08％）， 5 new general ADR cases （3.38％） and 2 new severe ADR cases （1.35％）. After symptomatic treatment， the total effective rate was 98.65％. CONCLUSIONS： ADR induced by monoclonal antitumor drugs appear in all ages， the primary disease is wide； it causes multiple systems/orgars involved and complex clinical manifestations， great harm. Therefore， great importance should be attached to rational drug use monitoring and countermeasures in order to improve the safety of drug use.